

Gastrointestinale Tumoren:

Nitrosamin-Kontaminationen in Fertigarzneimitteln (S. 18–26)

U. Gundert-Remy

1. World Health Organization; International Agency for Research on Cancer. IARC Monographs on the evaluation of the carcinogenic risks to humans. Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs Volumes 1 to 42. Supplement 7. Lyon: World Health Organization; 1987. (<http://monographs.iarc.fr/ENG/Monographs/suppl7/index.php>). Letzter Zugriff: 25.08.2021
2. European Medicines Agency; Committee for Medicinal Products for Human Use (CHMP). Assessment report: Referral under Article 31 of Directive 2001/83/EC angiotensin-IIreceptor antagonists (sartans) containing a tetrazole group. EMA/217823/2019. 14.02.2019. (https://www.ema.europa.eu/en/documents/variation-report/angiotensin-ii-receptorantagonists-sartans-article-31-referral-chmp-assessmentreport_en.pdf). Letzter Zugriff: 25.08.2021
3. European Medicines Agency; Committee for Medicinal Products for Human Use (CHMP). Sartan medicines: companies to review manufacturing processes to avoid presence of nitrosamine impurities. EMA/248364/2019 Rev 1. 17.04.2019. (https://www.ema.europa.eu/en/documents/referral/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-sartan-medicines-companies-review_en.pdf). Letzter Zugriff: 25.08.2021
4. Arzneimittelkommission der deutschen Ärzteschaft. Anmerkungen der AkdÄ zur Berechnung des Krebsrisikos von genotoxischen Substanzen wie NDMA (Stand: 09.01.2019). (<https://www.akdae.de/Arzneimittelsicherheit/Weitere/Archiv/2018/docs/20180731.html>). Letzter Zugriff: 25.08.2021
5. Richtlinie 2001/83/EG des europäischen Parlaments und des Rates vom 6. November 2001 zur Schaffung eines Gemeinschaftskodexes für Humanarzneimittel. (<https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:2001L0083:20070126:de:PDF>). Letzter Zugriff: 25.08.2021
6. Ray A, Atal S, Sadasivam B. Understanding the molecularpharmaceutical basis of sartan recalls focusing on valsartan. *Glob Cardiol Sci Pract* 2020; 2020: e202025
7. European Medicines Agency; Committee for Medicinal Products for Human Use (CHMP). Assessment report: Procedure under Article 5(3) of Regulation EC (No) 726/2004. Nitrosamine impurities in human medicinal products. EMA/369136/2020. 25.06.2020. (https://www.ema.europa.eu/en/documents/referral/nitrosamines-emea-h-a53-1490-assessment-report_en.pdf). Letzter Zugriff: 25.08.2021
8. World Health Organization. N-Nitrosodimethylamine. Concise International Chemical Assessment Document (CICAD) 38. Geneva: World Health Organization; 2002. (<http://www.inchem.org/documents/cicads/cicads/cicad38.htm>). Letzter Zugriff: 25.08.2021
9. Peto R, Gray R, Brantom P, Grasso P. Nitrosamine carcinogenesis in 5120 rodents: chronic administration of sixteen different concentrations of NDEA, NDMA, NPYR and NPIP in the water of 4440 inbred rats, with parallel studies on NDEA alone of the effect of age of starting (3, 6 or 20 weeks) and of species (rats, mice or hamsters). *IARC Sci Publ* 1984; 57: 627–65
10. Peto R, Gray R, Brantom P, Grasso P. Effects on 4080 rats of chronic ingestion of N-nitrosodiethylamine or N-nitrosodimethylamine: A detailed dose-response study. *Cancer Res* 1991; 51: 6415–51
11. Peto R, Gray R, Brantom P, Grasso P. Dose and time relationships for tumor induction in the liver and esophagus of 4080 inbred rats by chronic ingestion of N-nitrosodiethylamine or or N-nitrosodimethylamine. *Cancer Res* 1991; 51: 6452–69

12. Knekt P, Järvinen R, Dich J, Hakulinen T. Risk of colorectal and other gastro-intestinal cancers after exposure to nitrate, nitrite and N-nitroso compounds: a follow-up study. *Int J Cancer* 1999; 80: 852–56
13. Loh YH et al. N-Nitroso compounds and cancer incidence: the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk Study. *Am J Clin Nutr* 2011; 92: 1053–61
14. Keszei A et al. Dietary N-nitroso compounds, endogenous nitrosation, and the risk of esophageal and gastric cancer subtypes in the Netherlands Cohort Study. *Am J Clin Nutr* 2013; 97: 135–46
15. Zhu Y et al. Dietary N-nitroso compounds and risk of colorectal cancer: a case-control study in Newfoundland and Labrador and Ontario, Canada. *Br J Nutr* 2014; 111: 1109–17
16. Catsburg CE et al. Dietary sources of N-nitroso compounds and bladder cancer risk: findings from the Los Angeles bladder cancer study. *Int J Cancer* 2014; 134: 125–35
17. Zheng J et al. Dietary N-nitroso compounds and risk of pancreatic cancer: results from a large case-control study. *Carcinogenesis* 2018; 40: 254–62
18. Song P, Wu L, Guan W. Dietary Nitrates, Nitrites, and Nitrosamines Intake and the Risk of Gastric Cancer: A Meta- Analysis. *Nutrients* 2015; 7: 9872–95
19. Yoon HJ, Kim J-H, Seo GH, Park H. Risk of Cancer Following the Use of N-Nitrosodimethylamine (NDMA) Contaminated Ranitidine Products: A Nationwide Cohort Study in South Korea. *J Clin Med* 2021; 10(1): 153
20. Gomm W, Röthlein C, Schüssel K, Brückner G, Schröder H, Heß S, Frötschl R, Broich K, Haenisch B. N-nitrosodimethylamine-contaminated valsartan and the risk of cancer – a longitudinal cohort study based on German health insurance data. *Dtsch Arztebl Int* 2021; 118: 357–62
21. Bradford Hill A. The environment and Disease: Association or Causation? *Proc R Soc Med* 1965; 58(5): 295–300
22. Abdel-Tawab M et al. Valsartan – ZL findet NDMA in Tabletten. *Pharm Ztg* 2018; 163: 14–16
23. Valentin J. Basic anatomical and physiological data for use in radiological protection: reference values: ICRP Publication 89: Approved by the Commission in September 2001. *Ann ICRP* 2002; 32: 1–277
24. Mortensen A et al.; EFSA ANS Panel. Scientific Opinion on the re-evaluation of potassium nitrite (E 249) and sodium nitrite (E 250) as food additives. *EFSA Journal* 2017; 15: 4786
25. Environmental Protection Agency (EPA); Office of Water (4607M). Six-Year Review 3 Technical report Document for Nitrosamines. EPA 810-R-16-009. 2016. (<https://www.epa.gov/sites/production/files/2016-12/documents/810r16009.pdf>). Letzter Zugriff: 25.08.2021
26. EFSA Scientific Committee. Scientific Opinion on the applicability of the Margin of Exposure approach for the safety assessment of impurities which are both genotoxic and carcinogenic in substances added to food/feed. *EFSA Journal* 2012; 10: 2578–83
27. European Medicines Agency; Committee for Human Medicinal Products ICH guideline M7(R1) on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk. EMA/ CHMP/ICH/83812/2013. 25.08.2015. (https://www.ema.europa.eu/en/documents/scientific-guideline/ich-guidelinem7r1-assessment-control-dna-reactive-mutagenic-impuritiespharmaceuticals-limit_en.pdf). Letzter Zugriff: 25.08.2021

Prostatakarzinom:

Prostatabiopsie mit Smartglass und Augmented Reality (S. 27–29)

P. Sparwasser

1. Rouvière O et al. MRI-FIRST Investigators. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. *Lancet Oncol* 2019; 20: 100–9
 2. Drost FH et al. Prostate MRI, with or without MRI-targeted biopsy, and systematic biopsy for detecting prostate cancer. *Cochrane Database Syst Rev* 2019; 25: 4: CD012663
 3. Wegelin O et al. Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore versus Magnetic Resonance Imaging-transrectal Ultrasound fusion versus Cognitive Registration. Is There a Preferred Technique? *Eur Urol* 2017; 71: 517–31
 4. Khor WS et al. Augmented and virtual reality in surgery-the digital surgical environment: applications, limitations and legal pitfalls. *Ann Transl Med* 2016; 4: 454
 5. Sparwasser PM et al. Augmented reality and virtual reality in the operating theatre status quo und quo vadis. *Aktuelle Urol* 2018; 49: 500–8
 6. Borgmann H et al. Feasibility and safety of augmented reality-assisted urological surgery using smartglass. *World J Urol.* 2017; 35: 967–72
 7. Galati R et al. Experimental Setup Employed in the Operating Room Based on Virtual and Mixed Reality: Analysis of Pros and Cons in Open Abdomen Surgery. *J Healthc Eng* 2020; 2020: 8851964
 8. Giganti F, Moore CM. A critical comparison of techniques for MRI-targeted biopsy of the prostate. *Transl Androl Urol* 2017; 6: 432–43
 9. Pokorny MR et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. *Eur Urol* 2014; 66: 22–29
 10. Lee DJ et al. Comparative Effectiveness of Targeted Prostate Biopsy Using Magnetic Resonance Imaging Ultrasound Fusion Software and Visual Targeting: a Prospective Study. *J Urol* 2016; 196: 697–702
 11. Verma S et al. The Current State of MR Imaging-targeted Biopsy Techniques for Detection of Prostate Cancer. *Radiology* 2017; 285: 343–56
 12. Barkovich EJ, Shankar PR, Westphalen AC. A Systematic Review of the Existing Prostate Imaging Reporting and Data System Version 2 (PI-RADSv2) Literature and Subset Meta-Analysis of PI-RADSv2 Categories Stratified by Gleason Scores. *AJR Am J Roentgenol* 2019; 212: 847–54
 13. Yoon JW et al. Augmented reality for the surgeon: Systematic review. *Int J Med Robot* 2018; 14: e1914
-

Lymphome:

Mantelzell-Lymphom – State of the art (S. 48–50)

K. Recker

1. Kompetenznetz Maligne Lymphome. Dreyling M. Mantelzell-Lymphom. Stand 25.02.2019. <https://lymphome.de/mantelzell-lymphom/> Letzter Zugriff: 02.01.2022
2. Dreyling M et al. Onkopedia-Leitlinie Mantelzell-Lymphom. Stand Mai 2021. <https://www.onkopedia.com/de/onkopedia/guidelines/mantelzell-lymphom/@@guideline/html/index.html> Letzter Zugriff: 02.01.2022
3. Swerdlow SH et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. *Blood* 2016; 127: 2375–90
4. Dreyling M et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2017; 28 (Supplement 4): iv62–iv71

5. Hoster E et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. *Blood* 2008; 111: 558–65
 6. Hoster E et al. Prognostic Value of Ki- 67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network. *J Clin Oncol* 2016; 34: 1386–94
 7. Dreyling M et al. Early consolidation with myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression - free survival in mantle cell lymphoma: results of a prospective randomized trial of the European MCL Network. *Blood* 2005; 105: 267–84
 8. Hermine OE et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. *Lancet* 388: 565–75
 9. Kluin-Nelemans HC et al. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. *J Clin Oncol* 38: 248–56
 10. Visco C et al. Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. *Leukemia* 2021; 35: 787–95
 11. Trneny M et al. Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. *Lancet Oncol* 2016; 17: 319–31
 12. Ruan J et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. *N Engl J Med* 2015; 373: 1835–44
 13. Wang M et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. *N Engl J Med* 2020; 382: 1331–42
-

Supportivtherapie:

Chemotherapie-induzierte Polyneuropathie – Pathomechanismen und analgetische Lokalthherapie (S. 51–57)

J. Sachau, M. Sendel, R. Baron

1. Maihöfner C et al. Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin. *Support Care Cancer* 2021; 29: 4223–38
2. Seretny M et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. *Pain* 2014; 155: 2461–70
3. Staff NP et al. Chemotherapy-induced peripheral neuropathy: A current review. *Ann Neurol* 2017; 81: 772–81
4. Pachman DR et al. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). *J Clin Oncol* 2015; 33: 3416–22
5. Loprinzi CL et al. The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. *Cancer J* 2007; 13: 399–403
6. Mols F et al. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. *J Clin Oncol* 2013; 31: 2699–707
7. Eldridge S, Guo L, Hamre J. A Comparative Review of Chemotherapy-Induced Peripheral Neuropathy in In Vivo and In Vitro Models. *Toxicol Pathol* 2020; 48: 190–201

8. Balayssac D et al. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. *Expert Opin Drug Saf* 2011; 10: 407–17
9. Boyette-Davis JA et al. An updated understanding of the mechanisms involved in chemotherapy-induced neuropathy. *Pain Manag* 2018; 8: 363–75
10. Smith EML et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. *JAMA* 2013; 309: 1359–67
11. Yokoyama S et al. Treatment strategy of oxaliplatin-induced peripheral neuropathy: a retrospective, nationwide study. *Support Care Cancer* 2021; doi: 10.1007/s00520-021-06585-z
12. Schlereth T Deutsche Gesellschaft für Neurologie (Hrsg.), Leitlinien für Diagnostik und Therapie in der Neurologie., Diagnose und nicht interventionelle Therapie neuropathischer Schmerzen, S2k-Leitlinie, 2019. Available from: <https://dgn.org/leitlinien/II-030-114-diagnose-und-nicht-interventionelle-therapie-neuropathischer-schmerzen-2019/>
13. Durand JP et al. Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFOF, a randomized, double-blind, placebo-controlled phase III trial. *Ann Oncol* 2012; 23: 200–5
14. Kautio A-L et al. Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. *J Pain Symptom Manage* 2008; 35: 31–9
15. Mishra S et al. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. *Am J Hosp Palliat Care* 2012; 29: 177–82
16. Loprinzi CL et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. *J Clin Oncol* 2020; 38: 3325–48
17. Garassino MC et al. Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. *PLoS One* 2013; 8: e59981
18. Rao RD et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). *Cancer* 2007; 110: 2110–18
19. Galiè E et al. Tapentadol in neuropathic pain cancer patients: a prospective open label study. *Neurol Sci* 2017; 38: 1747–52
20. Nishikawa T et al. Combination Therapy of Pregabalin with Tramadol for Treatment of Peripheral Neuropathy in Patients with Gynecological Cancer Receiving Taxane Containing Chemotherapy. *Gan To Kagaku Ryoho* 2017; 44: 227–31
21. Cartoni C et al. Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma. *Support Care Cancer* 2012; 20: 2621–26
22. S3-Leitlinie Supportive Therapie; 2017; 558
23. Meier T et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. *Pain* 2003; 106: 151–58
24. Baron R et al. Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. *Clin Drug Investig* 2009; 29: 231–41
25. Kern K-U et al. Can treatment success with 5% lidocaine medicated plaster be predicted in cancer pain with neuropathic components or trigeminal neuropathic pain? *J Pain Res* 2013; 6: 261–80
26. Cabezón-Gutiérrez L et al. High-Dose 8% Capsaicin Patch in Treatment of Chemotherapy-Induced Peripheral Neuropathy. A Systematic Review. *J Pain Symptom Manage* 2020; 60: 1047–54.e1

27. Anand P et al. Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification. *J Pain Res* 2019; 12: 2039–52
28. Filipczak-Bryniarska I et al. High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience. *Med Oncol* 2017; 34: 162
29. Maihofner C, Heskamp M-L. Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. *Curr Med Res Opin* 2013; 29: 673–83
30. Ramnarine S et al. Investigating high-concentration 8% capsaicin patch in chronic cancer-treatment related peripheral neuropathic pain. *JCO* 2016; 34: 208
31. LE Marec C et al. Improvement of chemotherapy induced neuropathy (CIN) in cancer patients using capsaicin 8% patch. *JCO* 2016; 34: e14031
32. Abstracts of the 7th World Research Congress of the European Association for Palliative Care (EAPC). *Palliat Med* 2012; 26: 384–674
33. Winter J, Bevan S, Campbell EA. Capsaicin and pain mechanisms. *Br J Anaesth* 1995; 75: 157–68
34. Chiu IM, von Hehn CA, Woolf CJ. Neurogenic inflammation and the peripheral nervous system in host defense and immunopathology. *Nat Neurosci* 2012; 15: 1063–67
35. Mou J et al. Qutenza (capsaicin) 8% patch onset and duration of response and effects of multiple treatments in neuropathic pain patients. *Clin J Pain* 2014; 30: 286–94
36. Polydefkis M et al. The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. *Brain* 2004; 127: 1606–15
37. Forst T et al. The influence of local capsaicin treatment on small nerve fibre function and neurovascular control in symptomatic diabetic neuropathy. *Acta Diabetol* 2002; 39: 1–6